ALPHA-INTERFERON MODIFIES CORTICAL EEG ACTIVITY - DOSE-DEPENDENCE AND ANTAGONISM BY NALOXONE

被引:50
作者
BIRMANNS, B
SAPHIER, D
ABRAMSKY, O
机构
[1] LOUISIANA STATE UNIV,MED CTR,DEPT PHARMACOL & THERAPEUT,POB 33932,SHREVEPORT,LA 71130
[2] HADASSAH UNIV HOSP,DEPT NEUROL,NEUROPHYSIOL LAB,IL-91120 JERUSALEM,ISRAEL
[3] HEBREW UNIV JERUSALEM,HADASSAH MED SCH,IL-91010 JERUSALEM,ISRAEL
关键词
EEG; CNS; NALOXONE; ALPHA-INTERFERON; WAKE SLEEP;
D O I
10.1016/0022-510X(90)90007-A
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Activation of the immune system is believed to provide signals in the form of chemical messengers that are able to change neural activity in a variety of regions of the central nervous system. In studies designed to examine the effects of alpha-interferon (alpha-IFN) upon the central nervous system, recordings of cortical EEG were made following intracerebroventricular injection of various doses of the cytokine. Administration of 25 U of alpha-IFN increased the amount of wake and decreased the amount of desynchronized sleep in the first hour following injection; an increase in synchronization being seen in the third hour. alpha-IFN at 250 U increased the amount of synchronization and decreased the amount of desynchronized sleep in the EEG, principally in the second hour, with 2500 U having similar but more potent effects, mostly in the first hour. The (-mu) opiate receptor antagonist, naloxone, was found to decrease the amount of EEG synchronization and blocked the increases in synchronized sleep produced by 250 U alpha-IFN. The data suggest that interferon on increases EEG synchronization in a dose-dependent and specific manner, probably via central-mu-opiate receptors. The increased wake in the EEG following 25 U suggests, however, that another discrete effect of alpha-IFN may also exist.
引用
收藏
页码:22 / 26
页数:5
相关论文
共 49 条
[1]   NEUROPSYCHIATRIC MANIFESTATIONS OF HUMAN-LEUKOCYTE INTERFERON THERAPY IN PATIENTS WITH CANCER [J].
ADAMS, F ;
QUESADA, JR ;
GUTTERMAN, JU .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1984, 252 (07) :938-941
[2]   BEHAVIORALLY CONDITIONED IMMUNOSUPPRESSION [J].
ADER, R ;
COHEN, N .
PSYCHOSOMATIC MEDICINE, 1975, 37 (04) :333-340
[3]  
Ader R., 1981, PSYCHONEUROIMMUNOLOG, V1st ed.
[4]  
BARTROP RW, 1977, LANCET, V1, P834
[5]  
BESEDOVSKY HO, 1977, EUR J IMMUNOL, V7, P325
[6]  
BIZIERE K, 1985, NEURAL MODULATION IM, P81
[7]   COMMON PATHWAYS OF INTERFERON AND HORMONAL ACTION [J].
BLALOCK, JE ;
STANTON, JD .
NATURE, 1980, 283 (5745) :406-408
[8]   HUMAN-LEUKOCYTE INTERFERON - STRUCTURAL AND BIOLOGICAL RELATEDNESS TO ADRENOCORTICOTROPIC HORMONE AND ENDORPHINS [J].
BLALOCK, JE ;
SMITH, EM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1980, 77 (10) :5972-5974
[9]   HUMAN-LEUKOCYTE INTERFERON (HUIFN-ALPHA) - POTENT ENDORPHIN-LIKE OPIOID ACTIVITY [J].
BLALOCK, JE ;
SMITH, EM .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1981, 101 (02) :472-478
[10]   SLEEP PATTERN ALTERATIONS BY NALOXONE - PARTIAL PREVENTION BY HALOPERIDOL [J].
CIANCHETTI, C ;
MASALA, C ;
OLIVARI, P ;
GIORDANO, G .
PSYCHOPHARMACOLOGY, 1984, 83 (02) :179-182